Research programme: autoimmune disorders therapy - Trillium Therapeutics

Drug Profile

Research programme: autoimmune disorders therapy - Trillium Therapeutics

Alternative Names: Anti-CD32a monoclonal antibody; TTI-314

Latest Information Update: 12 Feb 2013

Price : $50

At a glance

  • Originator Arthron
  • Developer Trillium Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Fc gamma receptor IIA antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Immune thrombocytopenic purpura; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 12 Feb 2013 Discontinued - Preclinical for Systemic lupus erythematosus in Canada (Parenteral)
  • 12 Feb 2013 Discontinued - Preclinical for Rheumatoid arthritis in Canada (Parenteral)
  • 12 Feb 2013 Discontinued - Preclinical for Immune thrombocytopenic purpura in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top